Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



愛帝宮母嬰健康股份有限公司

AIDIGONG MATERNAL & CHILD HEALTH LIMITED

(Incorporated in Bermuda with limited liability)
(Stock code: 286)

UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND INSIDE INFORMATION

This announcement is made by Aidigong Maternal & Child Health Limited (the "Company") pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) ("SFO") and Rules 13.09 and 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange.

The board (the "**Board**") of directors (the "**Directors**") of the Company has noted the unusual price and trading volume movement of the shares of the Company on 23 January 2024.

After due enquiry by the Board, the Company was informed by Mr. Cheung Wai Kuen ("Mr. Cheung"), an executive director, the chairman of the Board and the chief executive officer of the Group, and Ms. Zhu Yufei ("Ms. Zhu"), the chairman of the Group's Maternal and Child Cluster Strategy Committee and the global president of the Maternal and Child Cluster, that due to unknown cause leading to a sharp decrease in the price of the Shares, the respective stock brokers of Mr. Cheung and Ms. Zhu were sold 162,000,000 ordinary shares of the Company (the "Shares") and 93,190,000 Shares (which were placed in securities trading accounts with margin facilities) held by Mr. Cheung and Ms. Zhu, respectively, were sold on the market as a result of forced sale (the "Forced Sale") on 23 January 2024, representing approximately 3.65% and 2.10%, respectively, of the total Shares.

Immediately before the completion of the Forced Sales, Mr. Cheung and Ms. Zhu held approximately 12.06% and 14.89% respectively of the total Shares. Immediately after completion of the Forced Sale and as at the date of this announcement, the percentage interest of Mr. Cheung and Ms. Zhu in the Company has been reduced to approximately 8.41% and 12.79% respectively of the total Shares.

The Board confirms that the Group's business operation remains normal and the Company's postpartum care service business will proceed as per the Group's 5-years 50-cities strategic plan, the Group will continue to achieve full coverage of the nationwide postpartum care service market through the Aidigong brand business, the Yuegege brand postpartum care centres and the combination of Aidigong brand centres. There is no material adverse change to the business operation of the Group.

The Board also wishes to inform its shareholders and potential investors that the Group is recently considering various ways of financing, including but not limited to bank financing, issuance of bonds, placing, rights issue etc., in order to strengthen the Group's liquidity position, expand the Group's business development and to exploit any opportunities to broaden or create synergy for the Group's postpartum care services business.

Having made such enquiry with respect to the Company as may be reasonable in the circumstances, the Board confirms that, save as disclosed above, it is not aware of any reasons for such price and volume movements or of any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under Part XIVA of the SFO.

Shareholders of the Company and potential investors are advised to exercise caution in dealing with the securities of the Company.

By Order of the Board

Aidigong Maternal & Child Health Limited

Cheung Wai Kuen

Chairman

Hong Kong, 23 January 2024

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Lin Jiang, Ms. Kai Xiang Mei, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Ms. Liang Linmin as non-executive Director and Mr. Wong Yiu Kit, Ernest, Mr. Lam Chi Wing, Mr. Huang Wenhua and Mr. Wang Qingyu, as independent non-executive Directors